Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

6/9/2023
BreakingDry EyeRegulation
Novaliq Gains US Approval of Vevye for the Signs and Symptoms of Dry Eye
Novaliq Gains US Approval of Vevye for the Signs and Symptoms of Dry Eye

Novaliq, of Heidelberg, Germany, reported June 8 that the US FDA had approved Vevye (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease. June 8 wa...

6/9/2023
BreakingRegulation
CorNeat Vision Gains US Clearance for EverPatch Ophthalmic Graft Material
CorNeat Vision Gains US Clearance for EverPatch Ophthalmic Graft Material

Israel-based CorNeat Vision reported June 8 that the US FDA had cleared itsEverPatch scleral reinforcement patch. The graft is the first synthetic, nondegradable tissue-integrating matrix for use i...

6/9/2023
BreakingDry EyeRegulation
HanAll’s Dry Eye Candidate Tanfanercept Misses Primary Endpoints in Phase III Trial
HanAll’s Dry Eye Candidate Tanfanercept Misses Primary Endpoints in Phase III Trial

South Korea-based HanAll Biopharma reported May 19 that its topical anti-inflammatory dry eye candidate tanfanercept missed its primary endpoints in the Phase III VELOS-3 trial. Tanfanercept did no...

6/9/2023
BreakingPharmaceuticalRegulation
Merck Sues US Government Over Medicare Drug Price Negotiation Program
Merck Sues US Government Over Medicare Drug Price Negotiation Program

Merck on June 6 sued the US Department ofHealth and Human Services (HHS) over Medicare’s plans to reduce drug prices under the Inflation Reduction Act of 2022, calling the price negotiation process...

6/9/2023
AIBreakingGlaucoma
Researchers Use AI to Find Better Drug Delivery Methods to Treat Glaucoma, Other Eye Disease
Researchers Use AI to Find Better Drug Delivery Methods to Treat Glaucoma, Other Eye Disease

Researchers at Johns Hopkins’ Wilmer Eye Institute reported May 24 that they and colleagues from the University of Maryland had used machine learning—a method employed to create artificial intellig...

6/9/2023
BreakingCataractDeals
Sightpath Integrates Another Mobile Business Into Services
Sightpath Integrates Another Mobile Business Into Services

Sightpath Medical, of Bloomington, Minnesota, announced June 5 that it would integrate Southern Surgical Support, a Knoxville, Tennessee, mobile cataract services company, into its business. The mo...

6/9/2023
BreakingDealsRetina
BioLight, Alexion Team Up on Diagnosis of Retinal Disease Through Tear Film
BioLight, Alexion Team Up on Diagnosis of Retinal Disease Through Tear Film

Israel’s BioLight Life Sciences and Alexion announced May 30 that they would collaborate on a study of new technology that has the potential to screen the tear film to diagnose retinal disease. The...

6/9/2023
BreakingRefractiveRegulation
US FDA Accepts NDA for Vyluma’s Pediatric Myopia Candidate
US FDA Accepts NDA for Vyluma’s Pediatric Myopia Candidate

Vyluma announced June 6 that the US FDA had accepted its new drug application (NDA) for lead compound NVK002 (low dose atropine 0.01%) for childhood myopia and set a Prescription Drug User Fee Act ...

6/9/2023
BreakingDealsFunding
CoFi Raises $3.5 Million to Support Ophthalmic Payment Platform
CoFi Raises $3.5 Million to Support Ophthalmic Payment Platform

Boston-based CoFi reported June 6 that it had closed a $3.5 million seed funding round. CoFi provides a multi-party payment platform for eye care practices offering elective ophthalmic procedures. ...

6/9/2023
BreakingDry EyeFunding
Oculis Reports Positive Topline Results in Phase III Trial of Eye Drop Candidate for DME
Oculis Reports Positive Topline Results in Phase III Trial of Eye Drop Candidate for DME

Swiss company Oculis reported May 22 positive topline results from the first stage of its Phase III trial of OCS-01 eye drops in diabetic macular edema (DME). OCS-01 is a high-concentration, topica...

6/2/2023
BreakingIOLIndiaRegulation
Hoya Recalls Vivinex iSert Toric IOLs
Hoya Recalls Vivinex iSert Toric IOLs

Hoya Surgical Optics has issued a recall in India and Australia of eight models of its Vivinex iSert Toric IOL manufactured from June 2022 to January 2023. India’s Central Drugs Standard Control Or...

6/2/2023
BreakingEuropeRegulationRetina
Roche Withdraws European Marketing Application for Susvimo
Roche Withdraws European Marketing Application for Susvimo

The European Medicines Agency (EMA) announced on May 25 that Swiss drugmaker Roche had withdrawn its marketing application for Susvimo, a refillable ocular implant for ranibizumab in wet age-relate...

Past News Stories

6/2/2023
BreakingClinical TrialDry EyeEurope
Redwood Pharma Reports Positive Results for RP501 Topical Candidate in Dry Eye
Redwood Pharma Reports Positive Results for RP501 Topical Candidate in Dry Eye

Sweden’s Redwood Pharma reported May 31 positive results from a clinical trial of RP501, the company’s IntelliGel-based topical first-line therapy candidate for dry eye disease. RP501 was safe and ...

6/2/2023
BreakingIndustryPharmaSurgical
Bausch + Lomb Elevates Business Unit Heads to Executive Management Team
Bausch + Lomb Elevates Business Unit Heads to Executive Management Team

Bausch + Lomb Chairman and Chief Executive Officer Brent Saunders continues to reshape his leadership team, after making his return to the company in February. The company announced June 1 that bus...

6/2/2023
BiosimilarsBreakingEuropeRetina
Stada, Xbrane Launch Ximluci Ranibizumab Biosimilar in Germany
Stada, Xbrane Launch Ximluci Ranibizumab Biosimilar in Germany

Sweden’s Xbrane Biopharma and its partner Stada, of Germany, announced May 26 that they had launched their ranibizumab biosimilar Ximluci in Germany. The biosimilar was approved in Europe in Novemb...

5/26/2023
BreakingClinical TrialRetina
Annexon’s Complement Therapy Candidate in GA Shows Preservation of Vision in Phase II Trial
Annexon’s Complement Therapy Candidate in GA Shows Preservation of Vision in Phase II Trial

Annexon reported May 24 that topline results from its ARCHER Phase II trial of ANX007 in patients with geographic atrophy (GA) demonstrated a statistically significant, dose-dependent preservation ...

5/26/2023
BreakingDiagnosticIOLRevenueSurgical
Ophthalmic Revenue Roundup for Carl Zeiss Meditec and Hoya
Ophthalmic Revenue Roundup for Carl Zeiss Meditec and Hoya

Carl Zeiss Meditec reported May 9 that its ophthalmic device revenue for the first three months of 2023 (the second quarter of its fiscal 2022/2023 year) totaled €384.4 million ($421 million, conve...

5/26/2023
BreakingRegulationScope of PracticeSurgical
Washington Governor Signs Law Expanding Scope of Practice for Optometrists
Washington Governor Signs Law Expanding Scope of Practice for Optometrists

Gov. Jay Inslee of Washington state on May 9 signed the Access to Eyecare Act, expanding the scope of practice for optometrists there to include: —Incision and excision of chalazion —Certain inject...

5/23/2023
ASCRSEyeceleratorMeetingNewsletter
Eyecelerator Draws Record Crowd Ahead of ASCRS Meeting
Eyecelerator Draws Record Crowd Ahead of ASCRS Meeting

Eyecelerator had the largest attendance at an ASCRS Eyecelerator meeting to date, with over 600 industry, investment, and clinical attendees registered for the event. The first panel of the day fea...

5/26/2023
DealsRegulationSurgical
Envision Healthcare, Amsurg to Separate Following Bankruptcy Filing
Envision Healthcare, Amsurg to Separate Following Bankruptcy Filing

KKR-backed Envision Healthcare reported May 15 that it had filed for Chapter 11 bankruptcy protection. The Nashville, Tennessee, company said it had entered into a restructuring support agreement w...

5/26/2023
BreakingDealsLaser
Lumibird to Acquire Prima Industrie’s High-Power Laser and Semiconductor Businesses
Lumibird to Acquire Prima Industrie’s High-Power Laser and Semiconductor Businesses

France-based Lumibird announced May 16 that it and Italy’s Prima Industrie had agreed on a deal for Lumibird to acquire Prima subsidiary Convergent Photonics, also of Italy, and the Convergent asse...

5/26/2023
BreakingDealsRetina
Mireca Reacquires All Rights to Retinal Candidates as Graybug, Now CalciMedica, Exits Ophthalmology
Mireca Reacquires All Rights to Retinal Candidates as Graybug, Now CalciMedica, Exits Ophthalmology

Germany’s Mireca Medicines announced May 24 that it had regained all intellectual property rights previously shared in a partnership with Graybug Vision, now CalciMedica. Graybug, of Redwood City, ...

5/26/2023
BreakingDiagnosticRegulationRetina
iHealthScreen Files for US FDA 510(k) Clearance for iPredict AI Screener in AMD
iHealthScreen Files for US FDA 510(k) Clearance for iPredict AI Screener in AMD

New York-based iHealthScreen announced May 23 that it had submitted its iPredict automated AI screening system for US FDA 510(k) clearance for early diagnosis of age-related macular degeneration (A...

5/26/2023
BreakingClinical TrialRegulationRetina
PharmAbcine Gets Green Light from Korean Regulators for Phase I Trial of Wet AMD Candidate
PharmAbcine Gets Green Light from Korean Regulators for Phase I Trial of Wet AMD Candidate

South Korea’s PharmAbcine announced May 23 that Korean regulators had cleared its investigational new drug application for a Phase I trial of PMC-403, the company’s candidate for wet age-related ma...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more